Cor, CuraGen deal

The companies signed a pharmacogenomics and product discovery collaboration under which CRGN will use its SeqCalling, GeneCalling and PathCalling SNP identification and differential gene expression technologies to identify drug targets. CORR will have rights to small molecule and inhibitory antibody therapies while CRGN retains rights to protein therapeutics. In addition, CRGN will apply its pharmacogenomics expertise to preclinical and research products in CORR's pipeline to help identify potential new indications for the products as well as potential adverse effects. ...